A Study of QLP2117 in Combination With QL2107 in Advanced Solid Tumor Patients

NCT06911827 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

149

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumor

Interventions

DRUG: QLP2117
DRUG: QL2107

Sponsor

Qilu Pharmaceutical Co., Ltd.